Capital International Sarl Bluebird Bio, Inc. Transaction History

Capital International Sarl

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$27.12 - $45.97 $2,820 - $4,780	-104 Closed	0 $0
Q4 2019 Feb 18, 2020	SELL	$46.96 - $61.67 $1.04 Million - $1.37 Million	-22,181 Reduced 99.53%	104 $9,000
Q3 2019 Nov 14, 2019	SELL	$59.47 - $93.1 $523,336 - $819,280	-8,800 Reduced 28.31%	22,285 $2.05 Million
Q2 2019 Aug 14, 2019	SELL	$75.84 - $105.21 $151,680 - $210,420	-2,000 Reduced 6.05%	31,085 $3.95 Million
Q1 2019 May 15, 2019	SELL	$64.44 - $104.11 $753,948 - $1.22 Million	-11,700 Reduced 26.12%	33,085 $5.21 Million
Q4 2018 Feb 14, 2019	BUY	$59.1 - $93.26 $371,443 - $586,139	6,285 Added 16.32%	44,785 $4.44 Million
Q3 2018 Nov 14, 2018	BUY	$88.86 - $117.49 $1.21 Million - $1.61 Million	13,670 Added 55.05%	38,500 $0
Q2 2018 Aug 14, 2018	BUY	$99.64 - $127.59 $602,224 - $771,153	6,044 Added 32.17%	24,830 $3.9 Million
Q1 2018 May 15, 2018	BUY	$105.8 - $150.94 $1.99 Million - $2.84 Million	18,786 New	18,786 $3.21 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Capital International Sarl, based on Form 13F filings with the SEC.

Stay updated on Capital International Sarl with notifications on news.